Aldevron Breakthrough Blog / Todd Howren, Ph.D.

Perspectives: Where do we go from here?

Wide-ranging potential for mRNA vaccines

Overnight success is often the result of years of effort and setbacks, which could be the life story of an mRNA pioneer, Dr. Katalin Karikó, now with the Perelman School of Medicine at the University of Pennsylvania. Karikó spent decades focusing her research on how mRNA could be used for therapies, which ultimately helped lead to the development of COVID-19 vaccines.

Read More

Capacity versus Capability

What do they mean for you?

Capacity: The total amount that can be contained or produced
Capability: The ability to do something
*As defined by the Cambridge Dictionary

One of the issues I’ve heard raised in our industry is about how we define capacity and capability. As you can see from the definitions above, these are two very different items. But what do these two terms mean with respect to the manufacture of mRNA drug substance and/or drug product?

Read More

RNA is Only One Ingredient in RNA Development

Defining paths and building relationships

While research into RNA, including mRNA and related derivatives, has been ongoing for almost 50 years, it’s taken the COVID-19 pandemic to accelerate the development of vaccines using this technology. mRNA provides an incredible opportunity to develop new treatments for viral based, genetically driven, or cancerous diseases.

Read More

Building an mRNA Ecosystem

Capacity is only part of the solution

During conferences and seminars this year, there has been one particular topic that has come to the fore regarding mRNA production – capacity. Most of the concern comes from the impression that there isn’t enough capacity to meet market demand.

Read More